GLUCOTROL XL SUMMARY
Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea class.
GLUCOTROL XL is indicated as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with type 2 diabetes formerly known as non-insulin-dependent diabetes mellitus (NIDDM) or maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory. GLUCOTROL XL is indicated when diet alone has been unsuccessful in correcting hyperglycemia, but even after the introduction of the drug in the patient's regimen, dietary measures should continue to be considered as important. In 12 week, well-controlled studies there was a maximal average net reduction in hemoglobin A1C of 1.7% in absolute units between placebo-treated and GLUCOTROL XL-treated patients.
In initiating treatment for type 2 diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed, cardiovascular risk factors should be identified, and corrective measures taken where possible.
If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea should be considered. If additional reduction of symptoms and/or blood glucose is required, the addition of insulin to the treatment regimen should be considered. Use of GLUCOTROL XL must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood-glucose control on diet alone also may be transient, thus requiring only short-term administration of glipizide.
Some patients fail to respond initially or gradually lose their responsiveness to sulfonylurea drugs, including GLUCOTROL XL. In these cases, concomitant use of GLUCOTROL XL with other oral blood-glucose-lowering agents can be considered. Other approaches that can be considered include substitution of GLUCOTROL XL therapy with that of another oral blood-glucose-lowering agent or insulin. GLUCOTROL XL should be discontinued if it no longer contributes to glucose lowering. Judgment of response to therapy should be based on regular clinical and laboratory evaluations.
In considering the use of GLUCOTROL XL in asymptomatic patients, it should be recognized that controlling blood glucose in type 2 diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes. However, in insulin-dependent diabetes mellitus controlling blood glucose has been effective in slowing the progression of diabetic retinopathy, nephropathy, and neuropathy.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Glucotrol XL (Glipizide)
Lipid profiling reveals different therapeutic effects of metformin and glipizide
in patients with type 2 diabetes and coronary artery disease. [2014]
CONCLUSIONS: Our findings revealed the differential therapeutic effects of
Effects of metformin versus glipizide on cardiovascular outcomes in patients with
type 2 diabetes and coronary artery disease. [2013]
CONCLUSIONS: Treatment with metformin for 3 years substantially reduced major
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With
Type 2 Diabetes and Coronary Artery Disease. [2012]
OBJECTIVEThe two major classes of antidiabetic drugs, sulfonylureas and
metformin, may differentially affect macrovascular complications and mortality in
diabetic patients. We compared the long-term effects of glipizide and metformin
on the major cardiovascular events in type 2 diabetic patients who had a history
of coronary artery disease (CAD).RESEARCH DESIGN AND METHODSThis study is a
multicenter, randomized, double-blind, placebo-controlled clinical trial...
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. [2011.09]
CONCLUSIONS: Despite similar 52-week glycemic efficacy, dapagliflozin reduced weight and produced less hypoglycemia than glipizide in type 2 diabetes inadequately controlled with metformin. Long-term studies are required to further evaluate genital and urinary tract infections with SGLT2 inhibitors.
Meal fat storage in subcutaneous adipose tissue: comparison of pioglitazone and glipizide treatment of type 2 diabetes. [2010.10]
Treatment of type 2 diabetes (T2DM) with pioglitazone changes abdominal fat in the opposite direction as treatment with glipizide. To determine whether these two medications affect adipose tissue meal fatty acid storage differently we studied 19 T2DM treated with either pioglitazone (n = 8) or glipizide (n = 11) and 11 non-DM control subjects matched for age, BMI, abdominal and leg fat...
Clinical Trials Related to Glucotrol XL (Glipizide)
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1) [Completed]
The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose
levels in participants with moderate or severe renal insufficiency.
To Demonstrate the Relative Bioequivalency Comparing Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets [Completed]
Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics [Completed]
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily
(QD), compared to glipizide in elderly diabetic patients who have not received treatment or
are on a single oral medication.
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1) [Completed]
The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in
participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis
who do not have adequate glycemic control.
Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects [Completed]
Diabetes mellitus is a growing global disease now and future, and in China, 1. 2 million
peoples per year have been diagnosed as diabetes mellitus. 90% diabetes mellitus patient is
Type 2 diabetes mellitus. Glipizide is a potent drug to service patients who suffer from
Type 2 disease. Little information has been presented for the relationship between CYP2C19
genetic polymorphism and glipizide, since recently the investigators reported that there
existed a tendency. In this study the investigators found that CYP2C19 polymorphism
significantly influenced the pharmacokinetics of glipizide.
Reports of Suspected Glucotrol XL (Glipizide) Side Effects
Blood Glucose Increased (19),
Malaise (18),
Drug Ineffective (14),
Cardiac Disorder (11),
Diabetes Mellitus (10),
Fall (10),
Blood Cholesterol Increased (9),
Rash (9),
Weight Increased (8),
Memory Impairment (8), more >>
|
|
|
|
Page last updated: 2015-08-10
|
